Your browser doesn't support javascript.
loading
Emerging targets in gastroesophageal adenocarcinoma: what the future looks like.
Petrillo, Angelica; Smyth, Elizabeth C; van Laarhoven, Hanneke W M.
Afiliação
  • Petrillo A; Medical Oncology Unit, Ospedale del Mare, Via E. Russo, Naples 80147, Italy.
  • Smyth EC; Cambridge University Hospitals NHS Foundation Trust, Cambridge, Cambridgeshire, UK.
  • van Laarhoven HWM; Department of Medical Oncology, Amsterdam UMC location University of Amsterdam, Amsterdam, The Netherlands.
Ther Adv Med Oncol ; 15: 17588359231173177, 2023.
Article em En | MEDLINE | ID: mdl-37197225
Gastroesophageal adenocarcinoma (GEA) is a heterogeneous disease with a poor prognosis. Chemotherapy has been the cornerstone in treating metastatic diseases. Recently, the introduction of immunotherapy demonstrated improved survival outcomes in localized and metastatic diseases. Beyond immunotherapy, several attempts were made to improve patient survival by understanding the molecular mechanisms of GEA and several molecular classifications were published. In this narrative review, we will discuss emerging targets in GEA, including fibroblast growth factor receptor and Claudin 18.2, as well as the accompanying drugs. In addition, novel agents directed against well-known targets, such as HER2 and angiogenesis, will be discussed, as well as cellular therapies like CAR-T and SPEAR-T cells.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Ano de publicação: 2023 Tipo de documento: Article